HKSE •
Healthcare •
Biotechnology •
Quote as of 09/10/2026 16:08
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeHKSE
Market Capitalization25,581 mln
Float1,170 mln
Earnings Date11/16/2026
EPS
0.63
Moderate
P / E
21.63
Premium valuation
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-0.52
Highly suspicious
1-Year Forecast
20.26
Exceptional upside
Relative Strength
23
/ 100
Significantly lagging
Business Description
InnoCare Pharma is a China-based drug company focused on finding and bringing to market new treatments for cancer and autoimmune conditions. Its lead product, Orelabrutinib, is an approved therapy used across a range of blood cancers and immune disorders, including various forms of lymphoma, lupus, and multiple sclerosis. The company also has a broad pipeline of additional medicines in development targeting conditions such as lung cancer, skin disorders, and other blood-related diseases. Founded in 2015 and headquartered in Beijing, InnoCare is working to expand its portfolio both within China and beyond.
